Jonathan M O Rawson
Overview
Explore the profile of Jonathan M O Rawson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rawson J, Donaldson E, ORear J, Harrington P
Clin Infect Dis
. 2024 Dec;
PMID: 39686795
Background: PAXLOVID consists of nirmatrelvir, an inhibitor of SARS-CoV-2 main protease (Mpro), copackaged with ritonavir, a pharmacokinetic enhancer. Nirmatrelvir/ritonavir received emergency use authorization in the United States in 2021 and...
2.
Harrington P, Cong J, Troy S, Rawson J, ORear J, Valappil T, et al.
MMWR Morb Mortal Wkly Rep
. 2023 Dec;
72(51):1365-1370.
PMID: 38127674
Rebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports...
3.
Nikolaitchik O, Islam S, Kitzrow J, Duchon A, Cheng Z, Liu Y, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(23):e2305103120.
PMID: 37252967
HIV-1 relies on host RNA polymeraseII (Pol II) to transcribe its genome and uses multiple transcription start sites (TSS), including three consecutive guanosines located near the U3-R junction, to generate...
4.
Struble E, Rawson J, Stantchev T, Scott D, Shapiro M
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242780
Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable...
5.
Rawson J, Nikolaitchik O, Yoo J, Somoulay X, Brown M, Mbuntcha Bogni F, et al.
mBio
. 2022 Aug;
13(5):e0222022.
PMID: 36036631
Frequent recombination is a hallmark of retrovirus replication. In rare cases, recombination occurs between distantly related retroviruses, generating novel viruses that may significantly impact viral evolution and public health. These...
6.
Rawson J, Nikolaitchik O, Shakya S, Keele B, Pathak V, Hu W
Microbiol Spectr
. 2022 Jun;
10(4):e0105322.
PMID: 35736240
HIV-1 must package its RNA genome to generate infectious viruses. Recent studies have revealed that during genome packaging, HIV-1 not only excludes cellular mRNAs, but also distinguishes among full-length viral...
7.
Nikolaitchik O, Liu S, Kitzrow J, Liu Y, Rawson J, Shakya S, et al.
Proc Natl Acad Sci U S A
. 2021 Dec;
118(50).
PMID: 34873042
To generate infectious virus, HIV-1 must package two copies of its full-length RNA into particles. HIV-1 transcription initiates from multiple, neighboring sites, generating RNA species that only differ by a...
8.
Rawson J, Duchon A, Nikolaitchik O, Pathak V, Hu W
Viruses
. 2021 Jan;
13(2).
PMID: 33498923
The 3C-like protease (3CL) of SARS-CoV-2 is considered an excellent target for COVID-19 antiviral drug development because it is essential for viral replication and has a cleavage specificity distinct from...
9.
Nikolaitchik O, Somoulay X, Rawson J, Yoo J, Pathak V, Hu W
J Virol
. 2020 Aug;
94(21).
PMID: 32796062
The viral protein Gag selects full-length HIV-1 RNA from a large pool of mRNAs as virion genome during virus assembly. Currently, the precise mechanism that mediates the genome selection is...
10.
Burdick R, Li C, Munshi M, Rawson J, Nagashima K, Hu W, et al.
Proc Natl Acad Sci U S A
. 2020 Feb;
117(10):5486-5493.
PMID: 32094182
HIV-1 capsid core disassembly (uncoating) must occur before integration of viral genomic DNA into the host chromosomes, yet remarkably, the timing and cellular location of uncoating is unknown. Previous studies...